DiaCarta

Executive Summary

DiaCarta is a precision molecular diagnostics company headquartered in Pleasanton, CA, founded in 2013. The company specializes in developing and commercializing highly sensitive tests for cancer detection, therapy selection, and monitoring, as well as infectious disease diagnostics. Its proprietary XNA (crosslinking nucleic acid) and isobDNA™ (isothermal strand displacement-based DNA amplification) platforms enable ultra-sensitive detection of genetic alterations, including mutations, fusions, and copy number variations, from liquid biopsies (e.g., blood, urine). These technologies offer significant advantages over conventional methods in terms of sensitivity, specificity, and turnaround time, positioning DiaCarta to address unmet needs in early cancer detection and minimal residual disease (MRD) monitoring.

Upcoming Catalysts (preview)

• Q3 2026Launch of liquid biopsy test for colorectal cancer screening70% success
• Q1 2027Strategic partnership with a top-10 pharma company for companion diagnostics50% success
• Q2 2026Series C funding round exceeding $50 million60% success